Helsinn to develop Zealand's diarrhoea therapy
This article was originally published in Scrip
Executive Summary
Helsinn Healthcare and Zealand Pharma will develop and commercialise ZP1846, a glucagon-like peptide-2 receptor agonist for the treatment of chemotherapy-induced diarrhoea.